Guerbet SA (GBT.PA) Stock
Guerbet SA provides a range of contrast media, medical devices, and digital and AI solutions for diagnostic and interventional imaging worldwide. It offers DOTAREM, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced MRI examinations; Elucirem, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced resonance imaging; UNIK, a diagnostic imaging interconnected solution; and Artirem, a gadoteric acid.
Valuation
Financials & Margins
Latest News
Valuation & Return Ratios
Ownership
Peer Comparison
About Guerbet SA
Guerbet SA provides a range of contrast media, medical devices, and digital and AI solutions for diagnostic and interventional imaging worldwide. It offers DOTAREM, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced MRI examinations; Elucirem, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced resonance imaging; UNIK, a diagnostic imaging interconnected solution; and Artirem, a gadoteric acid. The company also provides OptiStar Elite, a dual head contrast delivery system with an ultrasonic motor; Ready-Box, a contrast media warmer; MRI accessories and consumables for diagnostic imaging; OptiProtect 3S, a suite of services and support solution; Conray/Cysto-Conray, an iothalamate meglumine injection contrast agent for CT; Micropaque/Microtrast, a barium sulfate contrast agent for CT; Optiray, an ioversol contrast agent for CT and Cath lab; Telebrix Gastro, a meglumine ioxitalamate contrast agent for CT; and Xenetix/ScanBag by Xenetix, an Iobitridol contrast agent for CT and Cath lab. In addition, it offers OptiBolus, which allows for a uniform vascular enhancement throughout the procedure; OptiOne, a single head injector; OptiVantage Multi-use, an optimal power injector for X-ray procedures; OptiVantage, a dual-head CT contrast delivery injector; Illumena Néo, a multi-mode contrast delivery injector; Lipiodol Ultra Fluid, an iodinated ethyl ester of fatty acids of poppy seed oil; Qitexio, a range of lipiodol resistant medical devices consisting of medical syringes and a stopcock; Lipiodol Ultra Fluid for use in interventional radiology and women's health; and Patent Blue V, a pharmaceutical drug for breast cancer. The company was founded in 1901 and is headquartered in Villepinte, France.
Guerbet SA is led by CEO Karim Boussebaa, employs 2,700 people, headquartered in Villepinte, FR, publicly traded since 2000.
Guerbet SA (GBT.PA) stock trades at $8.05 with a market capitalization of $100.99M. The stock is valued at a price-to-earnings (P/E) ratio of 6.56, price-to-book of 0.38, price-to-sales of 0.13. Over the past 52 weeks the stock has ranged between $7.43 and $23.10, and currently trades 65.2% below its 52-week high.
On profitability, Guerbet SA generates a return on equity (ROE) of -34.58%, an operating margin of -1.70%, a net profit margin of -13.56%.
Official website: www.guerbet.com